How should we proceed with disease-modifying treatments for multiple sclerosis?
- 1 March 1997
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 349 (9052) , 586-587
- https://doi.org/10.1016/s0140-6736(05)61562-0
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosisAnnals of Neurology, 1995
- How Many People in the World Have Multiple Sclerosis?Neuroepidemiology, 1994
- Rating neurologic impairment in multiple sclerosisNeurology, 1983